ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Inhibitors that bind competitively to the ATP binding pocket in the kinase domain of the oncogenic fusion protein BCR–Abl1 are used successfully in targeted therapy of chronic myeloid leukemia (CML).